Cellectar Biosciences, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

NET LOSS PER SHARE

Schedule of dilutive securities have been excluded from the computation of diluted net loss per share


		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2024		2023		2024		2023
Warrants		20,412,789		27,148,243		20,412,789		27,148,243
Preferred shares on an as-converted-into-common-stock basis		6,015,662		111,111		6,015,662		111,111
Stock options		5,359,624		2,280,756		5,359,624		2,280,756
Total potentially dilutive shares		31,788,075		29,540,110		31,788,075		29,540,110


		Year Ended December 31,
		2023		2022
Warrants		26,923,243		6,714,479
Stock options		2,351,903		746,257
Convertible preferred shares		3,624,957		111,111
Total potentially dilutive shares		32,900,103		7,571,847